Consumer genetics pioneer 23andMe won a long-sought victory in April 2017, when the Food and Drug Administration granted them the first authorization to sell genetic health risk reports directly to consumers. The new reports cover gene variants that could increase the risk of developing late-onset Alzheimer's disease, Parkinson's disease, and eight other serious conditions--clearing the way for more such reports in the future. Since its launch in 2006, the company has collected DNA from more than 5 million customers with its mail-in spit test, currently priced at $199 for a report that covers health, ancestry, and other traits. Some 85% of customers consent to share their anonymized results--plus self-reported health information--with 23andMe’s research partners, who include biotechs like Pfizer and Genentech, the nonprofit Michael J. Fox Foundation, and CPG giant Procter & Gamble. Studies of the 23andMe database have identified new genetic markers for depression and Parkinson’s disease, and an internal drug-development division is using genetic leads to find treatments for other conditions. With $250 million in new funding in 2017, the company’s total valuation hit $1.5 billion.